ArticleCurrent oncology (Toronto, Ont.)2022

A Pan-Canadian Consensus Statement on First-Line PARP Inhibitor Maintenance for Advanced, High-Grade Serous and Endometrioid Tubal, Ovarian, and Primary Peritoneal Cancers.

Anna V Tinker et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.